Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05152797 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 10, 2021 (before its estimated January 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Prospective, multicenter, single-arm, open label, interventional basket trial to evaluate autologous tumor-infiltrating lymphocytes (TILs) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparation for the treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.
Trial Details
NCT Number NCT05152797
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Tongji Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University
Conditions
(from sponsor)		 Tumor Infiltrating Lymphocytes
Enrollment 91 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov